Evidence map›Paper›PMID 26514204›Full record

ReviewAnnual review of pharmacology and toxicology2016

MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Jiabei Liu, Shannon J Clough, Anthony J Hutchinson, Ekue B Adamah-Biassi, Marina Popovska-Gorevski, Margarita L Dubocovich

2 registry-linked trialsOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annual review of pharmacology and toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 300 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
300citing papers in PubMed, 6 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03590197 phase4completednot on this mapstarted 2018, after this paper: background citation

Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy: A Randomized, add-on Placebo-controlled Clinical Trial

TypeinterventionalSponsorAll India Institute of Medical Sciences, BhubaneswarRan2018 to 2020Enrolled104ConditionsGeneralized EpilepsyArmsMelatonin 3 mg, Placebo
NCT05922995 early_phase1terminatednot on this mapstarted 2023, after this paper: background citation

A Single Center, Open Label Prospective Observational Pilot Study to Evaluate the Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)

TypeinterventionalSponsorBrigham and Women's HospitalRan2023 to 2023Enrolled20ConditionsREM Behavior DisorderArmsTasimelteon
3 · Its place in the literature

Who cites it

300 citing papers in PubMed, 6 syntheses or guidelines pooled it, 610 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Gut microbes · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

240 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jiabei LiuDepartment of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York 14214; email: jl284@buffalo.edu , shannonc@buffalo.edu , ah64@buffalo.edu , eba@buffalo.edu , mgorevsk@buffalo.edu , mdubo@buffalo.edu.
Shannon J CloughDepartment of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York 14214; email: jl284@buffalo.edu , shannonc@buffalo.edu , ah64@buffalo.edu , eba@buffalo.edu , mgorevsk@buffalo.edu , mdubo@buffalo.edu.
Anthony J HutchinsonDepartment of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York 14214; email: jl284@buffalo.edu , shannonc@buffalo.edu , ah64@buffalo.edu , eba@buffalo.edu , mgorevsk@buffalo.edu , mdubo@buffalo.edu.
Ekue B Adamah-BiassiDepartment of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York 14214; email: jl284@buffalo.edu , shannonc@buffalo.edu , ah64@buffalo.edu , eba@buffalo.edu , mgorevsk@buffalo.edu , mdubo@buffalo.edu.
Marina Popovska-GorevskiDepartment of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York 14214; email: jl284@buffalo.edu , shannonc@buffalo.edu , ah64@buffalo.edu , eba@buffalo.edu , mgorevsk@buffalo.edu , mdubo@buffalo.edu.
Margarita L DubocovichDepartment of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York 14214; email: jl284@buffalo.edu , shannonc@buffalo.edu , ah64@buffalo.edu , eba@buffalo.edu , mgorevsk@buffalo.edu , mdubo@buffalo.edu.
University at Buffalo, State University of New York · US

Funding

Modulatory Role of Melatonin on CNS FunctionR01MH042922 · NIMH · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DUBOCOVICH, MARGARITA L · 1987 to 2008
$1.8M
Modulation of Methamphetamine Actions in the CNSR01DA021870 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DUBOCOVICH, MARGARITA L · 2007 to 2011
$1.6M
MELATONIN-LIGHT INTERACTION ON CIRCADIAN ACTIVITYR01MH052685 · NIMH · NORTHWESTERN UNIVERSITY · PI DUBOCOVICH, MARGARITA L · 1996 to 2003
$1.1M
Discovery of Selective MT1 Melatonin Receptor Ligands for Sleep DisordersR21NS061068 · NINDS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DUBOCOVICH, MARGARITA L · 2009 to 2010
$349k
NIDA NIH HHS DA02870NIDA NIH HHS R01 DA021870NIMH NIH HHS MH42922NIMH NIH HHS MH52585NIMH NIH HHS R01 MH042922NIMH NIH HHS R01 MH052685NINDS NIH HHS NS061068NINDS NIH HHS R21 NS061068Wellcome Trust
6 · The paper itself

Abstract

Melatonin, or 5-methoxy-N-acetyltryptamine, is synthesized and released by the pineal gland and locally in the retina following a circadian rhythm, with low levels during the day and elevated levels at night. Melatonin activates two high-affinity G protein-coupled receptors, termed MT1 and MT2, to exert beneficial actions in sleep and circadian abnormality, mood disorders, learning and memory, neuroprotection, drug abuse, and cancer. Progress in understanding the role of melatonin receptors in the modulation of sleep and circadian rhythms has led to the discovery of a novel class of melatonin agonists for treating insomnia, circadian rhythms, mood disorders, and cancer. This review describes the pharmacological properties of a slow-release melatonin preparation (i.e., Circadin®) and synthetic ligands (i.e., agomelatine, ramelteon, tasimelteon), with emphasis on identifying specific therapeutic effects mediated through MT1 and MT2 receptor activation. Discovery of selective ligands targeting the MT1 or the MT2 melatonin receptors may promote the development of novel and more efficacious therapeutic agents.

Indexed as

AnimalsCircadian RhythmHumansLigandsMelatoninNeoplasmsReceptor, Melatonin, MT1Receptor, Melatonin, MT2Sleep Wake DisordersLigandsMelatoninReceptor, Melatonin, MT1Receptor, Melatonin, MT2cancercircadian rhythm disordersdepressiondrugs of abuseneuroprotectionsleep disorders

Identifiers

PMID26514204
PMCPMC5091650
OpenAlexW2151132444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.